Akari Therapeutics receives positive opinion for orphan drug designation for Coversin
Akari Therapeutics announced the EMA Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan drug designation for Coversin for treatment of Guillain Barré Syndrome. Coversin is a second-generation complement inhibitor that acts on complement component-C5. May 23, 2016